Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GSK PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,660 GBX | +0.55% |
|
+3.03% | +14.47% |
| Feb. 09 | Moderna shares slide on concerns over drop in RSV vaccine efficacy | RE |
| Feb. 09 | Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy | RE |
| Sales 2023 | 30.33B 38.29B | Sales 2024 * | 31.55B 39.83B | Capitalization | 67.37B 85.05B |
|---|---|---|---|---|---|
| Net income 2023 | 4.93B 6.22B | Net income 2024 * | 5.65B 7.13B | EV / Sales 2023 | 2.45 x |
| Net Debt 2023 | 15.04B 18.99B | Net Debt 2024 * | 12.51B 15.79B | EV / Sales 2024 * | 2.53 x |
| P/E ratio 2023 |
11.9
x | P/E ratio 2024 * |
12
x | Employees | 69,400 |
| Yield 2023 |
4% | Yield 2024 * |
3.67% | Free-Float | 93.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on GSK plc
More press releases
| 1 day | +0.55% | ||
| 1 week | +3.03% | ||
| Current month | +5.87% | ||
| 1 month | +5.32% | ||
| 3 months | +17.28% | ||
| 6 months | +19.98% | ||
| Current year | +14.47% |
1 week
1 621.01
1 674.40
1 month
1 514.801 674.40
Current year
1 453.201 674.40
1 year
1 302.601 674.40
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Managers | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 19 M€ | +2.97% | - | |
| 2.51% | 4 M€ | +3.42% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 1,660 | +0.55% | 15,711,890 |
| 24-02-08 | 1,651 | -1.29% | 7,529,989 |
| 24-02-07 | 1,673 | +1.19% | 7,619,690 |
| 24-02-06 | 1,653 | -0.58% | 5,042,092 |
| 24-02-05 | 1,663 | +3.19% | 12,160,200 |
Delayed Quote London S.E., February 09, 2024 at 11:35 am EST
More quotes
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
Sector
Pharmaceuticals
Calendar
2024-02-21
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
16.6
GBP
Average target price
19.48
GBP
Spread / Average Target
+17.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.47% | 85 106 M $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ |
